San Diego-based Novocell--a stem cell engineering company--has raised $25 million in its third round of venture capital. Johnson & Johnson Development Corporation led the round and was joined by Sanderling Ventures, Asset Management Company and Pacific Horizon Ventures.
"Future milestones include the preclinical development of our diabetes cell therapy, enhancement of our cancer stem cell program to create new therapies for cancer and the development of additional cell therapies based on our significant know-how and research expertise in this arena," said Novocell CEO Alan J. Lewis.
- check out the release for more information
ALSO: Switzerland vaccine maker GlycoVaxyn has rounded up $9.3 million in its first round of venture capital. Sofinnova Partners and Index Ventures both increased their investment in the company after seeding the biotech in July 2006. The company is developing conjugated vaccines, which comprise an antigenic sugar residue and protein carrier (glycoproteins). Release
Related Articles:
Novocell scientists create insulin-producing cells. Report
Vaccine "renaissance" attracts huge new investments. Report